科研之友
微信
新浪微博
Facebook
分享链接
摘要
Emerging data describe new potential indications for tumor necrosis factor (TNF) inhibitors in dermatology, including pediatric psoriasis and hidradenitis suppurativa. New biosimilar TNF agents are in late stages of development and may be available in the United States in the near future. Biosimilar agents are similar but not identical to available TNF inhibitors, and approval requires extensive analytic, toxicily, pharmacokinetic, pharmacodynamic, and clinical testing.
- 出版日期2016-6
